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Abstract
Rationale: Previous respiratory diseases have been associated with
increased risk of lung cancer. Respiratory conditions often co-occur and
few studies have investigated multiple conditions simultaneously.
Objectives: Investigate lung cancer risk associated with chronic
bronchitis, emphysema, tuberculosis, pneumonia, and asthma.
Methods: The SYNERGY project pooled information on previous
respiratory diseases from 12,739 case subjects and 14,945 control
subjects from 7 case–control studies conducted in Europe and
Canada. Multivariate logistic regression models were used to
investigate the relationship between individual diseases adjusting
for co-occurring conditions, and patterns of respiratory disease
diagnoses and lung cancer. Analyses were stratiﬁed by sex, and
adjusted for age, center, ever-employed in a high-risk occupation,
education, smoking status, cigarette pack-years, and time since
quitting smoking.
Measurements and Main Results: Chronic bronchitis and
emphysema were positively associated with lung cancer, after
accounting for other respiratory diseases and smoking (e.g., in
men: odds ratio [OR], 1.33; 95% conﬁdence interval [CI], 1.20–1.48
and OR, 1.50; 95% CI, 1.21–1.87, respectively). A positive
relationship was observed between lung cancer and pneumonia
diagnosed 2 years or less before lung cancer (OR, 3.31; 95% CI,
2.33–4.70 for men), but not longer. Co-occurrence of chronic
bronchitis and emphysema and/or pneumonia had a stronger
positive association with lung cancer than chronic bronchitis
“only.” Asthma had an inverse association with lung cancer, the
association being stronger with an asthma diagnosis 5 years or
more before lung cancer compared with shorter.
Conclusions: Findings from this large international case–control
consortium indicate that after accounting for co-occurring
respiratory diseases, chronic bronchitis and emphysema continue
to have a positive association with lung cancer.
Keywords: epidemiologic study; lung neoplasm; pulmonary
disease; data pooling; case–control study
At a Glance Commentary
Scientiﬁc Knowledge on the Subject: Chronic bronchitis,
emphysema, tuberculosis, pneumonia, and asthma, when
examined individually, have been associated with an increased
risk of lung cancer diagnoses.
What This Study Adds to the Field: Our results from a large
pooled study show that chronic bronchitis and emphysema are
positively associated with lung cancer, after accounting for
other pulmonary diseases. The positive association between
pneumonia and lung cancer was stronger when diagnosed 2 years
or fewer before lung cancer diagnoses, compared with longer
intervals. Co-occurrence of chronic bronchitis and emphysema
and/or pneumonia had a stronger association with lung cancer,
compared with chronic bronchitis “only.” Asthma diagnosed 5
years or more prior was inversely related to lung cancer, and no
association was observed when asthma co-occurred with chronic
bronchitis.
Lung cancer is the most frequently diagnosed
cancer and the leading cause of cancer-related
deaths worldwide (1). Evidence suggests that
there is a relationship between previous
respiratory disease (PRD), including chronic
bronchitis, emphysema, tuberculosis, and
pneumonia, and lung cancer diagnoses (2).
Tobacco is a shared risk factor of PRD and
lung cancer. Yet, the mechanisms by which
PRD may independently inﬂuence lung
cancer risk are poorly understood, but it has
been hypothesized that inﬂammation caused
by PRD may act as a catalyst in
the development of lung neoplasms (3).
Much of the existing literature focuses
on individual PRDs, and does not account
for the high level of co-occurrence observed
among the various respiratory diseases. For
example, chronic obstructive pulmonary
disease (COPD) frequently co-occurs with
pneumonia (4) and a medical history of
respiratory disease early in life has been
related to a later increased risk of asthma,
chronic bronchitis, and emphysema (5).
The aim of this pooled analysis was
to investigate the relationship between
multiple PRDs and lung cancer risk in
a large multinational data set with detailed
information on smoking habits. To further
understand the role of PRD in lung cancer
etiology, we investigated the inﬂuence of
patterns of multiple respiratory diseases and
latency of PRD on lung cancer diagnoses.
Some of the results of this study have
been previously reported in the form of
a conference abstract (6).
Methods
The SYNERGY project is a consortium of
international lung cancer case–control studies
with information on occupational and lifetime
smoking histories (7, 8). More information
about the SYNERGY project is available
(http://synergy.iarc.fr). Of the participating
centers, 13 collected information on PRD.
Table 1 describes the characteristics of the
studies. Case subjects and control subjects
were frequency-matched for sex and age in
most studies. Interviews were predominantly
conducted through face-to-face interviews,
with the exception of the Montreal and
Toronto lung cancer studies, which used
telephone interviews. Individual countries in
the International Agency for Research on
Cancer (IARC) multicenter lung cancer study
in Central and Eastern Europe and the United
Kingdom (INCO) are included as individual
studies in these analyses. Ethical approvals
were obtained in accordance with legislation
in each country, and in addition by the
Institutional Review Board at the IARC.
In all studies PRD was self-reported
(“ever had” or “doctor diagnosed” a disease)
and most collected information on ﬁve
PRDs (chronic bronchitis, emphysema,
tuberculosis, pneumonia, and asthma).
INCO/LLP-UK study participants reported
“bronchitis” diagnoses. In the Montreal
study information on chronic bronchitis was
not collected and in the ICARE study
emphysema and pneumonia were omitted.
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The HdA and AUT studies were restricted
to PRDs diagnosed at least 2 years before
lung cancer diagnoses or control interview.
Statistical Analyses
Logistic regression models were ﬁtted
to calculate odds ratios (ORs) and 95%
conﬁdence intervals (CIs) of lung cancer
associated with PRDdiagnoses. All PRDswere
included in the same model to account for
multiple PRD diagnoses. As not all studies
collected information on all ﬁve PRDs, three
models were developed; the ﬁrst model
included all ﬁve PRDs (chronic bronchitis,
emphysema, tuberculosis, pneumonia, and
asthma); the second, four PRDs (chronic
bronchitis omitted); and the third, three PRDs
(emphysema and pneumonia omitted)
(Figure 1). Subjects with asbestosis (n = 89)
and silicosis (n = 110) were omitted, as these
diseases are causally associated with known
lung carcinogens. Analyses were stratiﬁed by
sex because of differences in smoking-related
exposures observed in men and women. The
potential effect of cigarette smoking status
was examined by stratifying the analyses;
former smokers (stopped >5 yr before lung
cancer diagnoses or control interview),
current smokers (>1 cigarette per day for>1
yr, and participants who quit ,5 yr before
lung cancer/interview), and never-smokers.
Analyses were also stratiﬁed by histological
subtype to investigate the association between
PRD diagnoses and subtypes of lung cancer.
A high level of co-occurrence was
observed among all PRDs, and thus further
analyses were restricted to studies and
participants with data on all ﬁve PRDs
(Figure 1). Patterns of PRD diagnoses with
20 or more case subjects and 20 or more
control subjects were investigated and
a categorical variable for each PRD was
created, indicating whether participants
reported the index respiratory disease only,
or other co-occurring PRD. Associations
were examined using logistic regression
models. Because of the small number
of women with speciﬁc PRD patterns,
only associations in men are reported.
The effect of latency of PRD diagnoses
on lung cancer risk was investigated in
studies with information on age at PRD
diagnoses (Figure 1). Three studies did not
collect year of PRD diagnoses (HdA, AUT,
and INCO/LLP-UK). A latency variable for
each PRD was created, indicating whether
the diagnoses had been made less than 2,
2–4, 5–9, or 10 or more years before lung
cancer/interview. Logistic regression models
were ﬁtted to categorical latency variables for
each PRD, and adjustments were made for
additional PRD diagnosed at any age.
Models were adjusted for center, age
(continuous), employment in an occupation
with an excess risk of lung cancer (“list A”
job [see Appendix E1 in the online
supplement; yes/no [9, 10]) and level
of education (none, ,6, 6–9, 10–13, .13
yr). Additional adjustments were made for
cigarette smoking status (current smokers,
former smokers, and never-smokers),
pack-years (+duration 3 average intensity
per day/20) and time-since-stopped smoking
cigarettes (2–7, 8–15, 16–25, .25 yr), where
appropriate. Subjects with missing data on
any covariates were omitted from analyses.
Meta-analyses and forest plots were
used to explore study-speciﬁc ORs and extent
of heterogeneity. Heterogeneity was assessed
using a chi-squared test of the Cochrane
Q statistic and I2 statistic. If there was
evidence of heterogeneity between studies,
outliers were identiﬁed using Galbraith
plots and removed in sensitivity analysis.
All analyses were conducted with Stata
version 11.0 for Windows (StataCorp LP,
College Station, TX). The Stata command
“metan” was used in the meta-analyses.
Results
Study Population
A description of the total study population
(12,739 case subjects and 14,945 control
subjects) is shown in Table 2. The median
age was 63 years for men and 62 years for
women. More case subjects than control
subjects were current smokers (71 vs. 26%
men and 61 vs. 20% women) and the mean
cumulative tobacco consumption (cigarette
pack-years) was higher in case subjects
compared with control subjects (men, 42.7
[SD 26.7] vs. 26.0 [SD 23.2]; women, 35.2
[SD 23.3] vs. 20.0 [SD 18.5]). A greater
proportion of women, both case subjects
and control subjects, were never-smokers,
and, on average consumed less tobacco,
compared with men. In case subjects,
squamous cell carcinoma was the most
frequently characterized histologic subtype
among men (41%), compared with
adenocarcinoma in women (44%).
PRD Prevalence
The most frequently reported PRDs were
pneumonia (25% of 10,194 case subjects and
Table 1. Description of Studies Included in Pooled Analysis
Study Acronym Country
Case Subjects Control Subjects
Data Collection Control TypeNumber
Response
Rate (%) Number
Response
Rate (%)
HdA Germany 1,004 69 1,002 68 1988–1993 Population
AUT Germany 3,180 77 3,249 41 1990–1995 Population
INCO-Czech Republic Czech Republic 304 94 452 80 1998–2002 Hospital
INCO-Hungary Hungary 391 90 305 100 1998–2001 Hospital
INCO-Poland Poland 793 88 835 88 1998–2002 Population and hospital
INCO-Romania Romania 179 90 225 99 1998–2001 Hospital
INCO-Russia Russia 599 96 580 90 1998–2000 Hospital
INCO-Slovakia Slovakia 345 90 285 84 1998–2002 Hospital
INCO/LLP-UK UK 442 78 917 84 1998–2005 Population
Montreal Canada 1,176 85 1,505 69 1996–2002 Population
EAGLE Italy 1,921 87 2,089 72 2002–2005 Population
ICARE France 2,926 87 3,555 81 2001–2006 Population
Toronto Canada 455 62 948 60 and 84 1997–2002 Population and hospital
Modified by permission from Reference 36.
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18% of 11,642 control subjects) and chronic
bronchitis (24% of 11,617 case subjects
and 15% of 13,451 control subjects).
Emphysema was the least frequently
reported PRD (5.0% of 10,106 case subjects
and 2.2% of 11,631 control subjects). There
was a high level of PRD co-occurrence; of
subjects with any PRD, between 50 and 83%
of case subjects and 40 and 83% of control
subjects reported another, dependent on
the index condition (Appendix E2). In
particular, a high proportion of participants
who reported emphysema (77% of 367 case
subjects and 83% of 206 control subjects) or
asthma (83% of 620 case subjects and 67% of
535 control subjects) reported another PRD.
PRD and Lung Cancer
In all models persons with chronic
bronchitis, emphysema, and pneumonia
had an increased risk of lung cancer,
compared with persons with no PRD
diagnoses. For men, relationships persisted
after further adjustment for “list A”
occupation, level of education, smoking
status, pack-years, and time-since-stopped
smoking (Table 3). There was little difference
in the strength of association among the
PRD models. For women, emphysema and
pneumonia remained positively associated
with lung cancer after adjustment for
confounding factors (not signiﬁcant for
emphysema). Chronic bronchitis was
associated with an increased risk of lung
cancer in the three-PRDmodel only (OR, 1.25;
95% CI, 1.07–1.47). No relationship between
tuberculosis and lung cancer was observed.
An inverse relationship between
asthma and lung cancer was observed in all
models. Effect estimates weakened and were
no longer signiﬁcant after controlling for
additional confounding factors for men,
except in the three-PRD model (OR, 0.86;
95% CI, 0.74–0.99). Among women, inverse
associations remained in the adjusted ﬁve-
and four-PRD models.
In the meta-analysis, there was
evidence of heterogeneity (P , 0.05) across
studies in the chronic bronchitis and
pneumonia models, and in the emphysema
and asthma models in men (Appendix E3).
When outliers were removed there was
little change in most of the effect estimates
(Appendix E4). For men, no association
was found between emphysema and lung
cancer (OR, 1.05; 95% CI, 0.68–1.55; I2,
27.9% after outliers removed). For
women, no association between
pneumonia and lung cancer was found
(OR, 0.95; 95% CI, 0.62–1.48; I2, 58.5%
after outliers removed).
Results stratiﬁed by smoking status
showed patterns of association in former
and current smokers similar to those
observed in the overall results (Appendix
E5). In never-smokers, numbers were small
and no signiﬁcant risk of lung cancer was
found in relation to any of the PRDs; an
inverse association between asthma and
lung cancer was, however, observed in men
in the four-PRD (OR, 0.39; 95% CI,
0.17–0.90) and three-PRD models (OR,
0.49; 95% CI, 0.24–0.98).
Results stratiﬁed by lung cancer
histological subtype showed that chronic
bronchitis and pneumonia were positively
associated with all lung cancer subtypes;
emphysema was positively related to
squamous cell and adenocarcinoma
(Appendix E6). Asthma was inversely
associated with all lung cancer subtypes
among women, and with adenocarcinoma
among men.
Patterns of PRD Diagnoses
Because of the high level of co-occurrence
among all PRDs and similar ﬁndings in all
models, the remaining analyses focused
on studies with data on all ﬁve PRDs.
The relationships between patterns of
PRD diagnoses and lung cancer in men are
shown in Table 4. Associations reﬂected
previous patterns observed in all models,
and relationships persisted after adjustment
for confounding factors (Table 4). Chronic
bronchitis “only” and pneumonia “only”
had a positive relationship with lung cancer
(OR, 1.39; 95% CI, 1.21–1.59 and OR,
1.23; 95% CI, 1.09–1.38, respectively), the
strength of association increasing when
they co-occurred, and when emphysema
was present. A large effect estimate was
observed for emphysema “only” (OR, 2.68;
95% CI, 1.71–4.21). An inverse relationship
was found between asthma “only” and lung
cancer (although not signiﬁcant). There was
no association between chronic bronchitis
Centers collected data on PRD (n=13)
Cases: 13,715; Controls: 15,947
Excluding participants diagnosed with asbestosis or silicosis
and with incomplete data on confounding factors.
Participants included in at least one model
Cases: 12,739; Controls: 14,945
PRD latency and lung
cancer (Table 5)
5 PRD model 4 PRD model 3 PRD model
Cases: 8,887
Controls: 10,082
Cases: 4,448
Controls: 4,912
Excluding
participants
without data on
age at PRD
diagnoses
Cases: 10,009
Controls: 11,576
Cases: 11,617
Controls: 13,451
ANALYSIS
PRD and lung cancer
(Table 3); stratified by
smoking status
(Appendix E5) and
histological subtype
(Appendix E6). 5 PRD
model only; PRD
patterns and lung
cancer (Table 4) and
meta-analysis
(Appendix E1, E2)
Figure 1. Flowchart of exclusion, participants, and analysis. PRD = previous respiratory disease.
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or pneumonia and lung cancer when either
co-occurred with asthma or tuberculosis.
Latency of PRD
In men, latency of chronic bronchitis and
emphysema had little effect on the
relationship with lung cancer (Table 5).
Relationships remained consistent for
chronic bronchitis after adjustment for
potential confounding factors. In the
adjusted model, there was little difference
in the strength of association between
emphysema at different latencies and
lung cancer; however, only emphysema
diagnosed 10 years or more before lung
cancer/interview remained statistically
signiﬁcant (OR, 1.94; 95% CI, 1.29–2.92). In
women, chronic bronchitis diagnosed 5 years
or more before lung cancer/interview and
emphysema diagnosed less than 4 years prior
were positively associated with lung cancer;
relationships attenuated after adjustment for
potential confounding factors.
Tuberculosis diagnosed 2–4 years prior
had an OR of 3.76 (95% CI, 1.05–13.56)
for men and an OR of 5.31 (95% CI,
0.54–51.77) for women, the effect estimates
remaining in the adjusted model (OR,
3.26; 95% CI, 0.80–13.25 and OR, 5.06;
95% CI, 0.44–58.33 for men and women,
respectively).
For pneumonia, effect estimates were
similar in both unadjusted and adjustedmodels
and stronger relationships were observed in
the shorter latencies, compared with longer;
for example, in men: OR, 3.31; 95% CI,
2.33–4.70 and OR, 1.82; 95% CI, 1.19–2.78 for
less than 2 and 5–9 years, respectively.
Asthma diagnosed at least 5 years
prior was inversely related to lung cancer
among men; weaker or no associations were
observed at other latencies. In women,
asthma diagnosed at least 2 years prior had
an inverse relationship with lung cancer
in both unadjusted and adjusted analyses,
although the 95% CI included the null effect.
Discussion
In this investigation we pooled data from
case–control studies in Europe and Canada
to examine the association between
multiple PRD and lung cancer. A high
Table 2. Description of Study Population
Men: %/Mean (n) Women: %/Mean (n)
Case Subjects
(n = 9,794)
Control Subjects
(n = 11,163)
Case Subjects
(n = 2,945)
Control Subjects
(n = 3,782)
Age (median), yr 63 62 61 62
Highest level of education
None 1.0 (96) 0.6 (72) 0.9 (25) 0.8 (29)
Some primary; ,6 yr 16.9 (1,656) 11.5 (1,284) 16.1 (474) 15.0 (568)
Primary/some secondary; 6–9 yr 52.0 (5,089) 45.2 (1,330) 43.8 (4,886) 38.5 (1,455)
Secondary/some college; 10–13 yr 17.6 (1,720) 22.3 (656) 21.9 (2,441) 25.4 (959)
University; .13 yr 12.6 (1,233) 22.2 (2,480) 15.6 (460) 20.4 (771)
“List A” occupation
Never 85.2 (8,347) 90.2 (10,073) 94.5 (2,871) 98.7 (3,734)
Ever 14.8 (1,447) 9.8 (1,090) 2.5 (74) 1.3 (48)
Smoking status
Never 2.4 (233) 23.5 (2,627) 25.4 (749) 59.0 (2,232)
Former (>5 yr) 26.6 (2,601) 43.6 (4,869) 14.0 (413) 18.3 (693)
Current 71.1 (6,690) 32.9 (3,667) 60.5 (1,783) 22.7 (857)
Pack-years; mean 42.7 (9,561) 35.2 (2,196) 26.0 (8,536) 20.0 (1,550)
Time since cessation of smoking
2–7 yr 12.6 (1,229) 7.5 (835) 8.9 (263) 4.7 (177)
8–15 yr 9.6 (944) 10.0 (1,120) 5.3 (156) 4.8 (180)
16–25 yr 8.2 (806) 13.8 (1,544) 3.8 (113) 5.9 (224)
>26 yr 4.8 (469) 16.0 (2,900) 2.0 (59) 5.4 (204)
Centers
HdA 7.9 (774) 7.2 (804) 5.4 (159) 4.3 (164)
AUT 26.2 (2,562) 23.8 (2,654) 17.5 (514) 14.4 (545)
INCO-Czech Republic 2.3 (229) 2.6 (289) 2.3 (68) 4.2 (158)
INCO-Hungary 3.2 (312) 2.2 (247) 2.9 (86) 1.7 (64)
INCO-Poland 5.6 (545) 5.1 (568) 8.2 (241) 6.8 (258)
INCO-Romania 1.4 (139) 1.4 (152) 1.4 (40) 2.0 (76)
INCO-Russia 5.3 (516) 4.5 (501) 2.7 (79) 2.0 (77)
INCO-Slovakia 2.9 (385) 2.1 (234) 2.0 (58) 1.3 (49)
INCO/LLP-UK 2.8 (272) 5.1 (564) 5.4 (158) 9.1 (343)
Montreal 6.5 (634) 7.7 (858) 14.8 (435) 15.9 (601)
EAGLE 15.4 (1,503) 14.3 (1,564) 13.5 (398) 13.1 (497)
ICARE 19.3 (1,888) 22.7 (2,560) 19.0 (558) 18.9 (716)
Toronto 1.4 (135) 1.5 (168) 1.4 (135) 6.2 (234)
Histologic type*
Squamous cell carcinoma 40.8 (3,966) 19.1 (560)
Small cell carcinoma 16.4 (1,594) 17.2 (504)
Adenocarcinoma 25.9 (2,520) 44.1 (1,291)
*The remaining case subjects had other or mixed histology types or information was missing (n = 2,304).
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level of co-occurrence among various PRDs
was observed. Chronic bronchitis and
emphysema were positively associated with
lung cancer, irrespective of the latency
between PRD diagnoses and lung cancer/
interview. Pneumonia had a positive
association with lung cancer, the
relationship being stronger for pneumonia
diagnosed less than 2 years before lung
cancer diagnoses compared with
those diagnosed later. Asthma had an
inverse association with lung cancer, the
association being stronger for asthma
diagnosed at least 5 years before lung
cancer compared with less than 5 years.
No association was observed between
tuberculosis and lung cancer after
accounting for confounding factors. Co-
occurrence of chronic bronchitis and
either/both emphysema and pneumonia
had a stronger positive association with
lung cancer than chronic bronchitis
“only,” with emphysema diagnoses being
particularly important. Chronic bronchitis
was not associated with lung cancer when
it co-occurred with asthma.
Methodological Considerations
The study strengths include the large sample
size and detailed information on lifetime
smoking history. Data on multiple PRDs
were collected, and thus the relationship
between patterns of PRD and lung cancer
could be investigated. Limitations include
some centers using hospital-based control
selection, the low response rate among
control subjects in the AUT study (40%),
and the small number of never-smokers.
There was limited detail on the respiratory
diseases, for example, investigation of atopic
and allergic subtypes of asthma was not
possible. The comparability of chronic
bronchitis between studies may be limited
due to differences in the deﬁnition of the
condition. Most studies reported diagnoses
of “chronic bronchitis,” whereas INCO/
LLP-UK studies used a broader deﬁnition
of the disease, asking participants whether
they had had “bronchitis,” which includes
acute and chronic subtypes. However,
sensitivity analysis excluding the INCO/
LLP-UK studies found little difference
in the results (data not shown).
Temporality is an important
consideration when investigating PRD and
lung cancer as some of the conditions
resemble the early symptoms of lung cancer.
Latency analysis was possible in studies that
collected age at PRD diagnoses. Excluding
participants without age at PRD diagnoses
reduced the sample size by almost 50%
and missing data may have inﬂuenced the
relationship between PRD and lung cancer.
However, overall patterns of association
were comparable between the full and
restricted study sample, indicating that
missing data may not have inﬂuenced
the associations (data not shown).
PRD diagnoses were self-reported and
participants may have misreported their
disease status (11, 12). The lack of medical
records or spirometry data limit the validity
of the disease deﬁnition, and this may have
varied by PRD. For example, diagnosis of
emphysema requires sensitive pulmonary
function tests compared with a sputum
test for tuberculosis. Studies that have
compared self-reported data and medical
records of chronic respiratory diseases have
found good agreement for the absence or
presence of asthma (13, 14), and moderate
to poor agreement for COPD, emphysema,
pneumonia, and tuberculosis (15, 16).
However, self-reported COPD has been
shown to have a high level of agreement
with spirometry results (17, 18). Recall
bias is a potential problem in all case–
control studies and it is possible that
misclassiﬁcation may have introduced some
bias here. Nevertheless, case subjects did
Table 3. Association between Previous Respiratory Disease Diagnoses and Risk of Lung Cancer; Odds Ratios and 95% Conﬁdence
Intervals Calculated Using Logistic Regression Models
Five-PRD Models Four-PRD Models* Three-PRD Models†
Case
Subjects
Control
Subjects OR
(95% CI)
Case
Subjects
Control
Subjects OR
(95% CI)
Case
Subjects
Control
Subjects OR
(95% CI)n % n % n % n % n % n %
Men 7,023 7,652 7,697 8,535 9,120 10,280
None 3,938 56.1 5,055 66.1 Ref 5,113 66.4 6,319 74.0 Ref 6,459 70.8 8,182 73.6 Ref
Bronchitis 1,639 23.3 1,176 15.4 1.33
(1.20–1.48)
2,166 23.8 1,442 14.0 1.52
(1.39–1.67)
Emphysema 346 4.9 176 2.3 1.50
(1.21–1.87)
398 5.2 204 2.4 1.68
(1.37–2.05)
Tuberculosis 349 5.0 323 4.2 1.00
(0.83–1.20)
364 4.7 341 4.0 1.01
(0.85–1.21)
461 5.05 427 4.15 1.10
(0.94–1.29)
Pneumonia 1,750 24.9 1,444 18.9 1.24
(1.13–1.37)
1,945 25.3 1,580 18.5 1.36
(1.24–1.48)
Asthma 372 5.3 402 5.3 0.89
(0.75–1.07)
424 5.5 468 5.5 0.96
(0.81–1.13)
540 5.9 614 6.0 0.86
(0.74–0.99)
Women 1,864 2,430 2,312 3,041 2,497 3,171
None 1,056 56.7 1,514 62.3 Ref 1,501 64.9 2,193 72.1 Ref 1,648 66.0 2,340 73.8 Ref
Bronchitis 484 26.0 487 20.0 1.12
(0.92–1.35)
673 27.0 567 17.9 1.25
(1.07–1.47)
Emphysema 65 3.5 43 1.8 1.35
(0.85–2.12)
97 4.2 54 1.8 1.42
(0.96–2.11)
Tuberculosis 97 5.2 100 4.1 1.16
(0.83–1.60)
108 4.7 111 3.7 1.10
(0.80–1.51)
133 5.3 130 4.1 1.21
(0.91–1.60)
Pneumonia 418 22.4 403 16.6 1.20
(1.00–1.44)
605 26.2 536 17.6 1.38
(1.18–1.62)
Asthma 139 7.5 224 9.2 0.75
(0.57–0.98)
199 8.6 299 9.8 0.74
(0.59–0.93)
233 9.3 286 9.0 0.90
(0.73–1.12)
Definition of abbreviations: CI = confidence interval; OR = odds ratio; PRD = previous respiratory disease.
Participants diagnosed with previous respiratory diseases at any age; participants may be diagnosed with more than one respiratory disease. Analyses
include the *Montreal study and the †ICARE study. All previous respiratory diseases included in the same model; further adjustment made for age and
center, “list A” occupation, level of education, smoking status, pack-years, and time-since-stopped smoking.
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not report all PRDs at a consistently higher
level than control subjects, as shown by
the positive association between chronic
bronchitis and emphysema with lung
cancer, null association for tuberculosis,
and an inverse relationship for asthma,
indicating that recall bias may not have had
a strong inﬂuence on the results (19).
Differences in the severity or treatment of
the PRD could also mean that participants
who report different diseases may
differently recall exposure to other risk
factors, such as smoking history. Never-
smokers were investigated in this study,
but because of small numbers, the results
were difﬁcult to interpret.
Interpretation of Findings and
Comparison with the Literature
Co-occurrence of PRD. Co-occurrence of
different pulmonary conditions was
common in the SYNERGY consortium,
as shown elsewhere. In particular, asthma
and emphysema were rarely reported in
isolation, compared with other PRDs. In an
Italian general population study 13% of
adults reported a physician’s diagnoses
of asthma and COPD, the proportion
increasing to 20% among participants aged
65 years and older (20). Clinical record
studies have reported high levels of co-
occurrence of respiratory diseases (21). An
American study found that 47% of patients
more than 65 years of age and hospitalized
for pneumonia had a comorbid chronic
pulmonary disease (22). Our estimates of
co-occurrence are at the upper end of
previously reported ﬁgures; of participants
who reported one PRD, 31.3% of case
subjects and 26.3% of control subjects
reported two or more PRDs. Respiratory
diseases often share symptoms, for
example, COPD and asthma. The overlap
of asthma and COPD diagnoses can reach
20% of all patients with chronic respiratory
disease (23). A previous diagnosis of
a respiratory disease is also associated
with an increased risk of future diagnoses
of another respiratory disease. Prior
tuberculosis infection has been associated
with irreversible airway obstruction and an
increased risk of COPD, and childhood
pneumonia is linked to an increased risk of
major respiratory diseases in adulthood
(24). Given the high proportion of patients
with multiple pulmonary diseases, it
is important to account for multiple
diagnoses when investigating the
independent contribution of each
respiratory disease to cancer risk.
Chronic bronchitis and emphysema and
lung cancer. Findings in this study of
a positive association between chronic
bronchitis and emphysema and lung cancer
are consistent with previous pooled analysis,
Table 4. Associations between Combinations of Previous Respiratory Disease Diagnoses and Lung Cancer in Men; Odds Ratios
and 95% Conﬁdence Intervals Calculated Using Logistic Regression Models
PRD Patterns
Control Subjects Case Subjects OR (95% CI)
n % n % Unadjusted Adjusted
Bronchitis (n = 11,808) 5,577 6,231
None 5,055 81.1 3,938 70.6 Ref Ref
Bronchitis only 577 9.3 751 13.5 1.81 (1.61, 2.04) 1.39 (1.21, 1.59)
Bronchitis and emphysema 37 0.6 77 1.4 2.69 (1.81, 4.01) 1.70 (1.09, 2.66)
Bronchitis and tuberculosis 29 0.5 33 0.6 1.62 (0.98, 2.70) 1.04 (0.59, 1.85)
Bronchitis and pneumonia 261 4.2 431 7.7 2.26 (1.92, 2.66) 1.83 (1.52, 2.20)
Bronchitis and asthma 112 1.8 78 1.4 1.04 (0.77, 1.40) 1.03 (0.73, 1.46)
Bronchitis and emphysema and pneumonia 28 0.5 57 1.0 2.60 (1.64, 4.11) 1.69 (1.02, 2.80)
Bronchitis and tuberculosis and pneumonia 32 0.5 53 1.0 2.25 (1.44, 3.52) 1.86 (1.13, 3.04)
Bronchitis and pneumonia and asthma 43 0.7 73 1.3 2.47 (1.68, 3.65) 1.99 (1.27, 3.11)
Emphysema (n = 9,515) 4,284 5,231
None 5,055 96.7 3,938 92.0 Ref Ref
Emphysema only 33 0.6 92 2.2 3.41 (2.28, 5.10) 2.68 (1.71, 4.21)
Emphysema and bronchitis 37 0.7 77 1.8 2.69 (1.80, 4.00) 1.67 (1.07, 2.61)
Emphysema and bronchitis and pneumonia 28 0.5 57 1.3 2.64 (1.67, 4.18) 1.69 (1.02, 2.80)
Pneumonia (n = 12,187) 5,688 6,499
None 5,055 77.8 3,938 69.3 Ref Ref
Pneumonia only 942 14.5 972 17.1 1.26 (1.14, 1.40) 1.23 (1.09, 1.38)
Pneumonia and bronchitis 261 4.0 431 7.6 2.10 (1.79, 2.48) 1.73 (1.44, 2.07)
Pneumonia and tuberculosis 57 0.9 58 1.0 1.21 (0.84, 1.75) 1.15 (0.75, 1.75)
Pneumonia and asthma 27 0.4 33 0.6 1.59 (0.94, 2.68) 1.46 (0.80, 2.68)
Pneumonia and bronchitis and emphysema 28 0.4 57 1.0 2.68 (1.70, 4.24) 1.71 (1.03, 2.83)
Pneumonia and bronchitis and tuberculosis 32 0.5 53 0.9 2.06 (1.32, 3.22) 1.74 (1.06, 2.85)
Pneumonia and bronchitis and asthma 43 0.7 73 1.3 2.27 (1.54, 3.34) 1.84 (1.18, 2.87)
Asthma (n = 9,767) 4,310 5,457
None 5,055 92.7 3,938 91.4 Ref Ref
Asthma only 150 2.8 82 1.9 0.76 (0.57, 1.01) 0.73 (0.53, 1.01)
Asthma and bronchitis 112 2.1 78 1.8 1.02 (0.76, 1.38) 1.01 (0.71, 1.43)
Asthma and pneumonia 27 0.5 33 0.8 1.62 (0.96, 2.74) 1.49 (0.81, 2.74)
Asthma and pneumonia and bronchitis 43 0.8 73 1.7 2.28 (1.55, 3.37) 1.87 (1.19, 2.93)
Definition of abbreviations: CI = confidence interval; OR = odds ratio; PRD = previous respiratory disease.
Participants diagnosed with index previous respiratory disease and other respiratory diseases at any age; that is, participants with data on all five PRDs.
Unadjusted models include age and center, adjusted models further adjust for “list A” occupation and level of education, smoking status, pack-years,
time-since-stopped smoking.
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Table 5. Association between Latency of Previous Respiratory Disease Diagnoses and Lung Cancer Using Logistic Regression
Models; Odds Ratios and 95% Conﬁdence Intervals Calculated Using Logistic Regression Models
Latency of
PRD Diagnoses*
Men Women
Case
Subjects
(n = 4,448)
Control
Subjects
(n = 4,912)
OR
(95% CI)
Case
Subjects
Control
Subjects
OR
(95% CI)
n % n % Model 1 Model 2 n % n % Unadjusted Adjusted
Bronchitis
(n = 7,116)
None 2,707 77.7 3,125 86.1 Ref Ref 797 75.8 1,115 81.3 Ref Ref
,2 yr 110 3.2 48 1.3 2.52
(1.78, 3.56)
1.78
(1.22, 2.61)
19 1.8 28 2.0 0.81
(0.44, 1.49)
0.58
(0.30, 1.15)
2–4 yr 60 1.7 43 1.2 1.51
(1.01, 2.25)
1.10
(0.71, 1.72)
24 2.3 30 2.2 0.98
(0.56, 1.72)
0.77
(0.42, 1.44)
5–9 yr 85 2.4 45 1.2 1.92
(1.32, 2.80)
1.76
(1.16, 2.68)
21 2.0 20 1.5 1.32
(0.70, 2.50)
0.98
(0.49, 1.96)
>10 yr 524 15.0 369 10.2 1.53
(1.31, 1.79)
1.30
(1.09, 1.55)
190 18.1 178 13.0 1.33
(1.02, 1.73)
1.18
(0.88, 1.59)
Emphysema
(n = 7,252)
None 3,332 93.7 3,612 97.7 Ref Ref 1,063 97.1 1,381 98.6 Ref Ref
,2 yr 35 1.0 12 0.3 3.04
(1.56, 5.94)
1.94
(0.96, 3.93)
12 1.1 5 0.4 3.17
(1.09, 9.17)
1.99
(0.62, 6.42)
2–4 yr 37 1.0 15 0.4 2.56
(1.39, 4.71)
1.98
(0.97, 4.03)
9 0.8 4 0.3 2.31
(0.70, 7.67)
1.17
(0.31, 4.34)
5–9 yr 40 1.1 17 0.5 2.34
(1.31, 4.18)
1.60
(0.84, 3.04)
3 0.3 4 0.3 0.94
(0.21, 4.31)
0.36
(0.06, 2.22)
>10 yr 111 3.1 41 1.1 2.42
(1.67, 3.51)
1.94
(1.29, 2.92)
8 0.7 7 0.5 1.14
(0.41, 3.22)
0.81
(0.26, 2.56)
Tuberculosis
(n = 7,276)
None 3,380 94.5 3,546 95.8 Ref Ref 1,038 94.5 1,352 96.6 Ref Ref
,2 yr 12 0.3 5 0.1 2.28
(0.79, 6.54)
1.37
(0.47, 3.98)
5 0.5 0 0.0
2–4 yr 12 0.3 3 0.1 3.76
(1.05, 13.56)
3.26
(0.80, 13.25)
3 0.3 1 0.1 5.31
(0.54, 51.77)
5.06
(0.44, 58.33)
5–9 yr 14 0.4 7 0.2 1.79
(0.71, 4.54)
1.03
(0.40, 2.65)
6 0.6 0 0.0
>10 yr 158 4.4 139 3.8 1.07
(0.84, 1.36)
1.06
(0.81, 1.39)
47 4.3 47 3.4 1.16
(0.76, 1.78)
1.12
(0.70, 1.79)
Pneumonia
(n = 7,188)
None 2,639 74.6 2,939 80.5 Ref Ref 860 79.3 1,152 83.5 Ref Ref
,2 yr 167 4.7 53 1.5 3.10
(2.25, 4.27)
3.31
(2.33, 4.70)
41 3.8 27 2.0 1.63
(0.98, 2.71)
1.21
(0.70, 2.08)
2–4 yr 68 1.9 50 1.4 1.30
(0.89, 1.90)
0.94
(0.63, 1.43)
20 1.9 26 1.9 0.89
(0.49, 1.63)
0.78
(0.40, 1.52)
5–9 yr 76 2.2 46 1.3 1.61
(1.10, 2.34)
1.82
(1.19, 2.78)
21 1.9 20 1.5 1.29
(0.68, 2.42)
1.07
(0.54, 2.14)
>10 yr 588 16.6 562 15.4 1.00
(0.88, 1.15)
1.04
(0.90, 1.21)
142 13.1 154 11.2 1.00
(0.77, 1.30)
0.90
(0.68, 1.20)
Asthma
(n = 7,253)
None 3,416 95.9 3,519 95.3 Ref Ref 1,020 93.2 1,276 91.7 Ref Ref
,2 yr 28 0.8 21 0.6 1.08
(0.60, 1.93)
1.21
(0.62, 2.40)
13 1.2 15 1.1 0.99
(0.45, 2.15)
1.32
(0.58, 3.00)
2–4 yr 20 0.6 14 0.4 1.15
(0.56, 2.34)
0.82
(0.37, 1.79)
11 1.0 20 1.4 0.65
(0.30, 1.39)
0.57
(0.24, 1.37)
5–9 yr 26 0.7 31 0.8 0.60
(0.35, 1.03)
0.44
(0.24, 0.79)
12 1.1 23 1.7 0.66
(0.32, 1.35)
0.64
(0.28, 1.43)
>10 yr 71 2.0 107 2.9 0.51
(0.37, 0.70)
0.67
(0.47, 0.98)
38 3.5 58 4.2 0.79
(0.51, 1.22)
0.83
(0.51, 1.35)
Definition of abbreviations: CI = confidence interval; OR = odds ratio; PRD = previous respiratory disease.
*Number of years index respiratory disease diagnosed before lung cancer diagnoses or control interview. Participants restricted to those with age of
diagnoses for index respiratory disease and complete data on other four respiratory diseases; that is, participants with data on five PRDs. Unadjusted
models include age and center, adjusted models further adjust for “list A” occupation and level of education, smoking status, pack-years,
time-since-stopped smoking.
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which also included the AUT, Toronto,
and INCO/LLP-UK studies. Brenner and
colleagues (2) observed an average overall
relative risk of 1.47 (95% CI, 1.29–1.68)
from 13 studies and 2.33 (95% CI,
1.86–2.94) from 16 studies for chronic
bronchitis and emphysema, respectively.
Comparable independent associations were
observed in this study, irrespective of
latency. Often chronic bronchitis and
emphysema are grouped together, along
with other pulmonary syndromes, into
COPD, despite heterogeneity in their
clinical presentation, physiology, response
to therapy, decline in lung function, and
survival (25). It is important to investigate
chronic bronchitis and emphysema
separately as grouping them may mask
differences in their association with lung
cancer. As shown here, individual
conditions and different patterns of PRD
had unique and independent associations
with lung cancer.
Emphysema was found to have
a stronger association with lung cancer,
compared with chronic bronchitis as well as
other PRDs. Studies that have investigated
chronic bronchitis and emphysema
separately have reported similar ﬁndings (2,
26). A 20-year follow-up study of 448,600
lifelong nonsmokers reported that lung
cancer mortality was signiﬁcantly
associated with both emphysema (hazard
ratio [HR], 1.7; 95% CI, 1.1–2.6), and
emphysema combined with chronic
bronchitis (HR, 2.4; 95% CI, 1.2–4.9), but
not with chronic bronchitis alone (HR,
1.0; 95% CI, 0.7–1.3) (27).
A potential explanation for the increase
in lung cancer risk is the inﬂammatory
response to chronic bronchitis and
emphysema, which is conducive to
tumor initiation (3). Increases in genetic
mutations, angiogenesis (28), and
antiapoptotic signaling (29) are potential
processes through which inﬂammation may
increase the risk of cancer development.
Pneumonia and lung cancer.
Pneumonia had a positive relationship with
lung cancer, but there was some indication
that the time between pneumonia and
lung cancer diagnoses may inﬂuence the
relationship. A stronger effect was shown
between pneumonia with shorter latencies
and lung cancer, compared with those
diagnosed later. In a prospective U.K. study
of primary care data, the association
between pneumonia and lung cancer was
inﬂuenced by timing of diagnoses; greater
effect estimates were observed with
pneumonia diagnosed within 6 months of
lung cancer diagnosis (OR, 13.3) compared
with 1–5 years (OR, 1.34) (30). People with
symptoms or diagnoses of a pulmonary
disease are more likely to undergo further
clinical investigation than those without,
providing greater opportunity for
a subsequent diagnoses of lung cancer. The
strong association with short latency may
also reﬂect reverse causality, as bronchial
suppression or immunosuppression caused
by a tumor may make patients more
susceptible to infection. The association
between pneumonia and lung cancer
may therefore be partially explained by
the misdiagnoses of early lung cancer
symptoms or ascertainment bias due to
increased monitoring of patients.
Asthma and lung cancer. Here an
inverse association between asthma and lung
cancer was observed, with the relationship
stronger with longer compared with shorter
latencies. A previous meta-analysis of
existing studies found a positive relationship
between asthma and lung cancer, with
a stronger relationship in recent studies and
shorter latencies (31). In subgroup analysis,
they stratiﬁed by other respiratory diseases
and found an inverse relationship between
asthma and lung cancer in studies that
adjusted for co-occurring chronic bronchitis,
emphysema, or COPD (shown in Table E1
in the online supplement). Rosenberger and
colleagues concluded that there was no clear
evidence of an independent association
between asthma and lung cancer (31).
Avoidance of known risk factors, such as
tobacco smoking, and working in “clean”
industries may partially explain the inverse
association and the strong association
observed among participants diagnosed
with asthma at least 10 years before lung
cancer/interview. A greater proportion
of participants who reported asthma
were classiﬁed as never-smokers (21%),
compared with those who reported
emphysema (9%), chronic bronchitis (14%),
and pneumonia (15%). It has been
hypothesized that asthma may reduce the
risk of lung cancer, thus counteracting the
association with other respiratory diseases,
through a more efﬁcient elimination of
abnormal cells (32). Long-term steroid
treatment (inhalers or tablets) can have
an important effect of the inﬂammation
pathway and could also biologically explain
the inverse relationship. Information on
treatment or grade of asthma was not
available in these studies and could not be
investigated here.
Tuberculosis and lung cancer. The
published literature on tuberculosis and
lung cancer is mixed. A meta-analysis found
that tuberculosis was associated with
adenocarcinoma lung cancer, but not
squamous or small cell carcinoma (33).
Findings from this study, of overall no
association between tuberculosis and lung
cancer, are consistent with a previous
investigation of tuberculosis which
accounted for co-occurring pulmonary
diseases, such as chronic bronchitis and
asthma (34). However, the number of
case subjects with tuberculosis in this
consortium was small and thus results
should be interpreted with caution.
Multiple PRDs and lung cancer. Our
study is one of a few that report on the
relationship between multiple types of
pulmonary diseases and lung cancer. There
was a stronger association with lung cancer
with increasing number of pulmonary
diseases (chronic bronchitis, emphysema,
and pneumonia). Yet, no association was
observed between chronic bronchitis and
lung cancer when asthma was also reported.
Other studies have observed similar results.
A Hong Kong longitudinal study that
grouped COPD and asthma observed no
association with lung cancer mortality in
female never-smokers (35). A Chinese
occupational cohort study examining
chronic bronchitis, asthma, and
tuberculosis found that only prior chronic
bronchitis was associated with an increased
lung cancer risk, with an adjusted HR of
1.50 (95% CI, 1.24–1.81), after including all
respiratory diseases in the same model (34).
A general practice study in the United
Kingdom found no independent
association between asthma and lung
cancer after excluding all patients with
a diagnoses of COPD (30).
Conclusions
Findings from this large international
case–control consortium indicate that
individual respiratory diseases may be
differentially associated with lung cancer,
after accounting for co-occurring PRD. The
pooling of data provided the power to
investigate multiple PRDs and different
histological subtypes of lung cancer, which
was not possible in the individual lung
cancer case–control studies. Respiratory
diseases, such as chronic bronchitis,
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emphysema, and asthma, are conditions
frequently found in the general population,
and thus identifying those at greater risk
would be of clinical importance. PRDs
frequently co-occur and in this study, the
relationship between different patterns of
PRD diagnoses and lung cancer varied,
with emphysema being particularly
important whereas co-occurring asthma
and chronic bronchitis were not associated
with lung cancer. The different associations
found with each PRD may support the
hypothesis of a different biological
mechanism underlying the etiological
pathway from a speciﬁc respiratory disease
to lung cancer. These ﬁndings could be
used to identify potentially vulnerable
groups, and inform the type and periodicity
of clinical surveillance recommended
for each PRD. Further investigation of
our observed associations is needed to
characterize high-risk groups, which could
then be used to develop opportunities for
early disease detection. n
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